VP.S ENCORE
Pre-clinical- Indications
- Organ preservation, Heart transplantation
Company intelligence / Profile preview
The company’s lead product, the VP.S ENCORE®, has received FDA Breakthrough Device Designation and has demonstrated successful preclinical results in over 100 ovine, porcine, and human hearts donated for research. It extends donor heart viability up to eight hours using a portable hypothermic machine perfusion approach with an acellular nutrient-rich solution. No clinical trial results are available yet as the device remains investigational.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vascular Perfusion Solutions.